Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0000875320-26-000094 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | 2026-02-17 | VRTX | McKechnie Duncan | EVP, Chief Commercial Off | F - Tax | $483.75 | -1,148 | 23.3K | -5% | -$555.3K | |
| 2026-02-19 | 2026-02-17 | VRTX | McKechnie Duncan | EVP, Chief Commercial Off | A - Grant | $0.00 | +4,962 | 24.5K | +25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | F | D | 1,148 | $483.75 | 23,342 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-17 | A | A | 4,962 | $0.00 | 24,490 | D | — | — | (F1) Restricted stock unit award that vests in installments beginning on February 20, 2027. |